9月5日港股创新药ETF（159567）份额减少9000.00万份，最新份额65.78亿份，最新规模66.97亿元

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) experienced a significant increase of 5.25% on September 5, with a trading volume of 1.89 billion yuan, indicating strong investor interest in the innovative drug sector [1] Group 1: Fund Performance - The fund's latest net asset value is calculated at 6.697 billion yuan, reflecting a robust performance since its inception [1] - Since its establishment on January 3, 2024, the fund has achieved a return of 103.62%, showcasing its strong growth potential [1] - Over the past month, the fund has delivered a return of 5.12%, indicating positive short-term performance [1] Group 2: Fund Management - The fund is managed by Yinhua Fund Management Co., Ltd., with Ma Jun serving as the fund manager [1] - The performance benchmark for the fund is the Guozhen Hong Kong Stock Connect Innovative Drug Index return rate, adjusted for valuation exchange rates [1] Group 3: Fund Size and Activity - The fund's share count decreased by 90 million shares on the reporting day, bringing the total shares to 6.578 billion [1] - Over the last 20 trading days, the fund's shares have increased by 1.207 billion, indicating growing investor confidence [1]